Q-Med AB has receives tender offer
The Board of Q-Med AB has received a tender offer from Ivytan AB ("Ivytan"), indirectly owned by EQT V ("EQT") and Lyftet Holding B.V. ("Lyftet"), one of Bengt Ågerup's ("Ågerup") controlled companies, for the acquisition of all shares in
Q-Med AB (publ) ("Q-Med") for 39 SEK cash per share. The shares in Q-Med are listed on NASDAQ OMX Stockholm AB ("OMX"), the Nordic List, Mid Cap.
Q-Med's Board was informed of the offer over the weekend. The Board will evaluate all aspects of Ivytan AB's offer and will make any decisions that the situation may require. In accordance with the provisions of the Guide to Public Takeovers, the Board will establish a committee of the independent members who will duly submit a recommendation to Q-Med's shareholders prior to the expiration of the time stipulated for acceptance.
Queries should be addressed to:
Pia Rudengren, Chairman of the Board
Mobil: +46 (0)706 242041
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: [email protected]. Web: www.q-med.com.
In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.
Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHATM, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, MacrolaneTM for body contouring, DurolaneTM for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and SolestaTM for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.